Inhale gains respiratory drug delivery technology:
This article was originally published in Clinica
Executive Summary
Inhale Therapeutic Systems is to acquire Alliance Pharmaceutical's PulmoSpheres particle and particle processing technology for use in respiratory drug delivery for $15 million in cash and $5 million in Inhale shares. San Carlos, California-based Inhale will get $5 million of Alliance stock. Alliance will also get future milestone payments and retains the right to develop up to two respiratory products based on the technology. The technology is designed to enhance the efficiency and reproducibility of drugs which are delivered in propellant-based metered-dose inhalers and dry powder inhalers.